This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message
Select 9 document(s) Sort by: PublicationDate
|
Entrez PubMed Results |
Items 1 -9 of 9
|
1: |
|
|
|
|
The significance of crossovers after randomization in the
STICH trial. |
|
|
2: |
||
|
|
The STICH trial: what does it tell us and where do we go
from here? |
|
|
3: |
|
|
|
|
Recombinant activated factor VII for acute intracerebral
hemorrhage. |
|
|
4: |
||
|
|
Early surgery versus initial conservative treatment in
patients with spontaneous supratentorial intracerebral haematomas in the
International Surgical Trial in Intracerebral Haemorrhage (STICH): a
randomised trial. |
|
|
5: |
||
|
|
Safety and feasibility of recombinant factor VIIa for
acute intracerebral hemorrhage. |
|
|
6: |
|
|
|
|
|
Neurological and functional status 1 year after acute spinal
cord injury: estimates of functional recovery in National Acute Spinal Cord
Injury Study II from results modeled in National Acute Spinal Cord Injury
Study III. |
|
|
|
7: |
|
|
|
|
Tissue plasminogen activator for acute ischemic stroke.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke
Study Group. |
|
|
8: |
|
|
|
|
A randomized, controlled trial of methylprednisolone or
naloxone in the treatment of acute spinal-cord injury. Results of the Second
National Acute Spinal Cord Injury Study. |
|
|
9: |
|
|
|
|
Efficacy of methylprednisolone in acute spinal cord
injury. |
|